Salt Lake City, UT (PRWEB) August 28, 2013
TFX Health, LLC announced earlier this week that its popular joint health supplement TFX Flex™ is now available at the online retail giant Amazon.com. In addition to several important vitamins and joint health nutrients, TFX Flex™ contains a breakthrough new dietary ingredient that has been proven in human clinical studies to be 2X more effective than glucosamine & chondroitin for joint pain relief.
According to a TFX Health company spokesman, “Amazon is one of the most important online outlets for health and wellness products in the world. It provides another channel for those seeking new and improved solutions to joint health problems.” In addition to Amazon, TFX Flex™ is also available at GNC and other retail distribution channels. Since its launch earlier this year, TFX Flex™ has become GNC’s best selling triple threat product for bone, joint, and muscle health.
Since its introduction at Amazon, sales of TFX Flex™ have exceeded expectations. The product continues to rack up positive five star reviews from satisfied customers.
J. Monnier, reported, “The usual daily pain in my joints is much less with this product. I noticed a difference by the end of the first week.” Another satisfied customer, M. Jacobsen, explained, “After two knee surgeries, I was skeptical after trying just about everything out there for my knee aches so I’m glad that I gave this a shot as it worked great, and I was feeling results in less than a week.” F. Stelson claimed, “I have used a number of different kinds of glucosamine, chondroitin, and cartilage derivatives for Osteoarthritis, mainly in my hips. This one seems to work noticeably better than what I had been using before.”
The launch of TFX Flex™ earlier this year quickly captured the attention of the joint health industry after glucosamine & chondroitin came under fire in a 2010 study published in the British Medical Journal. The study concluded that, “Glucosamine and Chondroitin, either taken together or separately, have not shown a clinically significant improvement in joint pain relief for patients troubled with knee or hip osteoarthritis [BMJ 2010; 341:c4675].
Worldwide annual sales of glucosamine & chondroitin have been estimated at more than $2 billion, with half of that coming from the United States. A spokesman for TFX Health explained, “The science behind joint health is changing and consumers are actively looking for better alternatives to glucosamine & chondroitin. TFX Flex™ has been shown in human clinical studies to be 2X more effective than glucosamine & chondroitin and it is the only product on the market that takes an overall approach to bone, muscle, and joint health.
TFX Flex™ contains a breakthrough new dietary ingredient known as UC-II® Undenatured Type II Collagen that has been proven in human clinical studies to be 2X more effective than glucosamine & chondroitin for joint pain relief. It was developed by a team of scientists with more than 25 years of experience in the development of patented dietary ingredients. The new ingredient holds 7 patents and is supported by multiple clinical studies, including research at Harvard University.
In a randomized, double-blind, placebo-controlled human clinical study published in the International Journal of Medical Sciences it was found that only 40 mg of UC-II® was more than two times as effective as 1,500 mg of glucosamine and 1,200 mg of chondroitin in supporting joint health, comfort and flexibility. It outperformed the glucosamine & chondroitin combination in three different joint pain relief assessment tools: WOMAC, VAS and the Lequesne Functional Index [Int J Med Sci. 2009; 6:312-321].
About TFX Health, LLC
Based in Salt Lake City, TFX Health, LLC is an innovative pioneer in the development of advanced health and wellness products. All products are manufactured in the USA in FDA registered, GMP compliant facilities and sold worldwide through online and traditional retail channels.
UC-II® is a trademark of InterHealth N.I. Clinical data available upon request. U.S. Patents 5,645,851; 5,637,321; 5,529,786; 5,750,144; 7,083,820; 7,846,487, EPO Patent 1435906B1 and worldwide patents pending.